Editorially Independent content supported with advertising by Genentech
Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD
Show Description +
How do you manage a patient with DME whose inability to arrive at the clinic may be adversely affecting her disease course? Jordan M. Graff, MD, reviews the case of a patient who fits this description, and discuss the value of retinal dryness and non-steroidal approaches to DME therapy. In this particular case, Dr. Graff begins with samples of faricimab (Vabysmo, Genentech), moves to step therapy–mandated bevacizumab (Avastin, Genentech), then onto bevacizumab in one eye and faricimab in the contralateral eye, and then finally onto insurance-approved faricimab.
Posted: 10/03/2023
Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD
How do you manage a patient with DME whose inability to arrive at the clinic may be adversely affecting her disease course? Jordan M. Graff, MD, reviews the case of a patient who fits this description, and discuss the value of retinal dryness and non-steroidal approaches to DME therapy. In this particular case, Dr. Graff begins with samples of faricimab (Vabysmo, Genentech), moves to step therapy–mandated bevacizumab (Avastin, Genentech), then onto bevacizumab in one eye and faricimab in the contralateral eye, and then finally onto insurance-approved faricimab.
Posted: 10/03/2023
Please log in to leave a comment.